FDA approves Sutent for rare type of pancreatic cancer

Posted by Food and Drug Administration--Press Releases on Friday May 20, 2011 Under News

The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

Be Sociable, Share!

Comments are closed.